TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03714451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: onyx sorghum
Description: The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whole wheat flour
Description: Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
Study: NCT02712008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3
Description: Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3
Description: Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3
Description: Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3
Description: Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3
Description: Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept Injection (IAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Study: NCT01250392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Effect of Active Choice on Nurse Visit Participation
Description: The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Effect of Active Choice on Nurse Visit Participation
Description: The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment.
Study: NCT04668365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg twice daily continuous oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT03378791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate Oral Tablet
Study: NCT02666404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement
Description: We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
Study: NCT00815100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
Study: NCT04246866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM103
Description: GEM103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM103
Description: GEM103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM103
Description: GEM103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM103
Description: GEM103
Study: NCT01164488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Repeated daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Repeated daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Repeated daily doses
Study: NCT02701296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine with Epinephrine
Description: Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
Study: NCT00764166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + hormonal treatment (LH-RH agonist)
Description: Docetaxel will be administered:~* To D1 of every cycle in the dose of 70 mg/m²,~* Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal treatment (LH-RH agonist)
Description: Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
Study: NCT03653364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
Study: NCT01692769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Study: NCT02386332

Intervention type: PROCEDURE
Intervention: transplantation

Intervention type: PROCEDURE
Intervention: transplantation
Study: NCT01052974

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine
Description: A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo.
Study: NCT00914641

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban IR
Description: immediate release tablet, 10 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban MR1
Description: modified release tablet 1, 10 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban MR2
Description: modified release tablet 2, 10 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban MR3
Description: modified release tablet 3, 10 mg, single dose
Study: NCT01687920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (1.25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (2.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (7.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862 (10mg)
Study: NCT01138462

Intervention type: OTHER
Group type: OTHER
Intervention: intervention
Description: 5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation.
Study: NCT03333512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
Study: NCT02411669

Intervention type: OTHER
Intervention: Operational patient centered care tools
Description: The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done.
Study: NCT04638036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescent molecular endoscopy and surgery
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
Study: NCT04545931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation
Description: 34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Acetate
Description: 0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
Study: NCT01888991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Preload and Exercise Intervention
Description: A glucose preload and exercise were administered to examine the modulate substrate oxidation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Preload and Exercise Intervention
Description: A glucose preload and exercise were administered to examine the modulate substrate oxidation
Study: NCT01243203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Champix
Description: Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
Study: NCT01751243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allo-depleted lymphocyte infusion
Description: Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allo-depleted lymphocyte infusion
Description: Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allo-depleted lymphocyte infusion
Description: Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allo-depleted lymphocyte infusion
Description: Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allo-depleted lymphocyte infusion
Description: Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Haploidentical transplantation of hematopoietic progenitors
Description: Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
Study: NCT03206606

Intervention type: DEVICE
Intervention: SPIRO
Description: Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
Study: NCT03416517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 or 8 mg/d po D1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 or 8 mg/d po D1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
Study: NCT03157999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (CAST)
Description: Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~* care coordination and system navigation (including facilitating timely primary care follow-up);~* medication management;~* assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~* evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~* patient and caregiver education; and goal setting and problem-solving therapy.
Study: NCT02308904

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw/Semen Exam
Description: Females:~1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~1. Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~2. Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older).

Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective data/Chart Review/Relevant Clinical Results
Description: 1. 1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2\* MRI. 4. Ferritin levels.~2. NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~3. 1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~4. 1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~5. Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement.

Intervention type: OTHER
Group type: OTHER
Intervention: Pituitary MRI
Description: MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted.
Study: NCT01132768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
Study: NCT03795545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy
Study: NCT00992485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADIPOPLUS
Description: autologous adipose-derived stem cell
Study: NCT05255133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Description: Blood sampling will be done at regular intervals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
Description: Scans will be done at regular intervals
Study: NCT06607393

Intervention type: DRUG
Intervention: Pembrolizumab

Intervention type: DRUG
Intervention: Pemetrexed

Intervention type: DRUG
Intervention: Pemetrexed

Intervention type: DRUG
Intervention: Cisplatin

Intervention type: DRUG
Intervention: Cisplatin

Intervention type: DRUG
Intervention: Carboplatin

Intervention type: DRUG
Intervention: Carboplatin
Study: NCT03591003

Intervention type: DIAGNOSTIC_TEST
Intervention: Yellow fever neutralizing antibodies measure
Description: Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
Study: NCT01817998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
Study: NCT03433768

Intervention type: GENETIC
Intervention: Real time PCR
Description: We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.

Intervention type: GENETIC
Intervention: Real time PCR
Description: We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
Study: NCT00113217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV on day 1 of each 14-day cycle.
Study: NCT02110550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPS.emmax endocrown